Mesoblast (NASDAQ:MESO) Trading Up 4.9% – Should You Buy?

Mesoblast Limited (NASDAQ:MESO)’s stock price was up 4.9% on Tuesday . The stock traded as high as $10.35 and last traded at $10.21. Approximately 11,724 shares traded hands during trading, a decline of 98% from the average daily volume of 770,086 shares. The stock had previously closed at $9.73.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MESO shares. Piper Sandler upgraded Mesoblast from a “neutral” rating to an “overweight” rating and upped their target price for the company from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, September 24th. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Mesoblast presently has an average rating of “Moderate Buy” and an average target price of $11.50.

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The business has a 50 day moving average of $8.20 and a 200-day moving average of $7.49.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MESO. GAMMA Investing LLC increased its stake in Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after acquiring an additional 1,663 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Mesoblast during the 2nd quarter worth about $562,000. Chapin Davis Inc. boosted its holdings in shares of Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after purchasing an additional 5,000 shares during the last quarter. Rathbones Group PLC acquired a new position in Mesoblast in the second quarter valued at approximately $95,000. Finally, Signaturefd LLC lifted its stake in Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares in the last quarter. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.